Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath
- 1 July 2013
- journal article
- review article
- Published by Elsevier BV in Annales Pharmaceutiques Francaises
- Vol. 71 (4), 203-215
- https://doi.org/10.1016/j.pharma.2013.05.002
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Towards prognostic biomarkers in pulmonary arterial hypertensionEuropean Respiratory Journal, 2012
- Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertensionEuropean Respiratory Journal, 2011
- Classification of breast cancer precursors through exhaled breathBreast Cancer Research and Treatment, 2010
- Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensorsBritish Journal of Cancer, 2010
- Basic Science of Pulmonary Arterial Hypertension for CliniciansCirculation, 2010
- Sniffing the Unique “Odor Print” of Non‐Small‐Cell Lung Cancer with Gold NanoparticlesSmall, 2009
- Diagnosing lung cancer in exhaled breath using gold nanoparticlesNature Nanotechnology, 2009
- Treatment of Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2004
- Halothane, isoflurane and sevoflurane inhibit NADH: ubiquinone oxidoreductase (complex I) of cardiac mitochondriaJournal Of Physiology-London, 2002
- The influence of cytochrome P450 enzyme activity on the composition and quantity of volatile organics in expired breathBiomarkers, 1996